IP Library Granted Patent US 11,891,662
Granted Patent B2
US 11,891,662 · App. 16/700,824 · Granted Feb 6, 2024

Polynucleotides for amplification and detection of human beta actin

Inventors: Jason M. Casolari (San Francisco, CA); Xuewen Jiang (Foster City, CA); Hédia Maamar (San Jose, CA)
Assignee: Talis Biomedical Corporation
C12Q1/6876C12Q1/6806C12Q1/6816
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,891,662
App. No.
16/700,824
Granted
Feb 6, 2024
Kind
B2
Abstract

Disclosed herein are primers and probes related to the detection of beta actin [ Homo sapiens (human)] via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of β-actin present in test samples. Specifically, the present disclosure describes primers and probes that bind to the beta actin gene for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.

Claims (12)

1. A composition comprising a set of primers comprising set-29, wherein set-29 comprises primer sequences of SEQ ID NO: 132 and SEQ ID NO: 133.

2. The composition of claim 1 , further comprising a probe.

3. The composition at claim 1 , further comprising a labeled probe, wherein the probe sequence comprises SEQ ID NO:184.

4. The composition of claim 2 , wherein the probe is a molecular beacon comprising a fluorophore and a quencher.

5. A molecular beacon probe comprising a fluorophore and a quencher, wherein the probe sequence comprises SEQ ID NO: 184.

6. A kit comprising a composition according to claim 1 .

7. A method of detecting β-actin in a test sample, the method comprising:

(a) extracting nucleic acid from the test sample;

(b) amplifying a target sequence by reacting nucleic acid extracted in step (a) for less than ten minutes with a reaction mixture comprising a strand displacement DNA polymerase and a sequence-specific isothermal loop mediated amplification (LAMP) primer set; and

(c) detecting the presence or absence of an amplified product of step (b); wherein the presence of said amplification product is indicative of the presence of β-actin in the test sample,

wherein said sequence-specific LAMP primer set is set-29, wherein set-29 comprises primer sequences of SEQ ID NO: 132 and SEQ ID NO: 133.

8. The method of claim 7 , wherein detecting the presence or absence of the amplification product comprises hybridizing the amplified product with a molecular beacon probe, wherein the probe sequence comprises SEQ ID NO: 184.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE STATE/COUNTRY ON THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 66986 FRAME: 149. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 11, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 067097/0916 →
CHANGE OF ADDRESS FROM 3400 BRIDGE PARKWAY, REDWOOD CITY TO 1100 ISLAND DRIVE, SUITE 101, REDWOOD CITY. Recorded Apr 2, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066986/0144 →
CHANGE OF ADDRESS FROM 1100 ISLAND DRIVE, SUITE 101, REDWOOD CITY TO 1375 WEST FULTON MARKET, SUITE 700, CHICAGO. Recorded Apr 2, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066986/0149 →
CHANGE OF ADDRESS FROM 230 CONSTITUTION DRIVE, MENLO PARK TO 3400 BRIDGE PARKWAY, REDWOOD CITY. Recorded Mar 27, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066926/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: CASOLARI, JASON M.; JIANG, XUEWEN; MAAMAR, HÉDIA
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 052601/0493 →
Continuity (1)
Related Publication 20210164043A1 · Jun 3, 2021